A judge or­ders Mar­tin Shkre­li to zip it -- af­ter Twit­ter shuts down his lat­est on­line ac­count

A fed­er­al judge told Mar­tin Shkre­li to shut up about his se­cu­ri­ties fraud case while he’s in and around the cour­t­house. And just be­fore lawyers ar­gued over a prospec­tive gag or­der, Twit­ter shut and locked the back door Shkre­li had ev­i­dent­ly found to worm his way back on­to the so­cial me­dia plat­form.

Ear­ly this morn­ing I no­ticed that@BLM­Bro is now miss­ing in ac­tion, sus­pend­ed by the pow­ers that be at Twit­ter, which had banned Shkre­li af­ter he be­gan ha­rass­ing a free­lance jour­nal­ist.

Over the week­end, The New York Times iden­ti­fied @BLM­Bro as his lat­est Twit­ter han­dle, where he has en­joyed roast­ing crit­ics and be­ing praised by his fans for his opin­ions on vir­tu­al­ly every­thing. The 34-year-old is on tri­al for de­fraud­ing in­vestors, but he’s far bet­ter known for jack­ing the price of a gener­ic drug by more than 5000%.

Shkre­li man­aged to sur­prise just about every­one by am­bling in­to the press area on Fri­day to chat with re­porters cov­er­ing his tri­al, slam­ming the pros­e­cu­tors as “ju­nior var­si­ty,” mock­ing the first wit­ness for the pros­e­cu­tion and shred­ding the air of qui­et that the de­fense ex­pects from their clients dur­ing the course of a tri­al. Pros­e­cu­tors want it to stop, de­mand­ing that the de­fen­dant be gagged — some­thing that no one has yet man­aged to do.

“Un­for­tu­nate­ly, de­spite the as­sur­ances of de­fense coun­sel pri­or to tri­al—as well as ef­forts by de­fense coun­sel to con­trol Shkre­li—once the ju­ry was se­lect­ed and em­pan­eled, Shkre­li em­barked on a cam­paign of dis­rup­tion by com­ment­ing on tri­al ev­i­dence and wit­ness­es to the press and on so­cial me­dia, and by mak­ing a spec­ta­cle of him­self and the tri­al di­rect­ly on the cour­t­house grounds,” pros­e­cu­tors ar­gued, ac­cord­ing to The Dai­ly Beast.

Shkre­li’s at­tor­ney al­ready has pushed back against the gag or­der, ac­cord­ing to CN­BC, ar­gu­ing that the ex-Retrophin CEO isn’t try­ing to harm the in­tegri­ty of the pro­ceed­ings.

“Rather his com­ments are the some­what nat­ur­al, though un­for­tu­nate, con­se­quence of a young man with a demon­strat­ed his­to­ry of sig­nif­i­cant anx­i­ety be­ing at the cen­ter of a supreme­ly dif­fi­cult time in his life,” Ben­jamin Braf­man wrote, ac­cord­ing to CN­BC. Shkre­li feels he’s been un­fair­ly tar­get­ed by the feds, adds the at­tor­ney, and jour­nal­ists fre­quent­ly fo­cus on the neg­a­tive when it comes to their cov­er­age. “Hav­ing said that, we al­so note that Mr. Shkre­li is un­der enor­mous pres­sure that is com­pound­ed by his clear­ly frail emo­tion­al state.”

Pros­e­cu­tors al­so re­vealed this morn­ing that Shkre­li’s de­fense team had asked about a plea deal, the lat­est in a se­ries of con­tra­dic­tions Shkre­li has faced in the court­room.

Shkre­li, for his part, still rou­tine­ly takes to live streams and any oth­er pub­lic stages to ex­pound on the case, in­vest­ing, news cov­er­age of his tri­al and more.

But Twit­ter is once again off lim­its.

For now.

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

Paul Hudson, Getty Images

UP­DAT­ED: Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that he’s pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research — which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now it’s pulling out entirely. As part of the pullback, it’s dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history,” Hudson said on a call with reporters, according to the Wall Street Journal. “As tough a choice as that is, we’re making that choice.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.

What does $6.9B buy these days in on­col­o­gy R&D? As­traZeneca has a land­mark an­swer

Given the way the FDA has been whisking through new drug approvals months ahead of their PDUFA date, AstraZeneca and their partners Daiichi Sankyo may not have to wait until Q2 of next year to get a green light on trastuzumab deruxtecan (DS-8201).

The pharma giant this morning played their ace in the hole, showing off why they were willing to commit to a $6.9 billion deal — with $1.35 billion in a cash upfront — to partner on the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.

Large advertisements for the drug Vivitrol decorate the walls of Grand Central Station on June 15, 2017 in New York City. (Photo: Andrew Lichtenstein via Getty)

FDA slaps down Alk­er­mes for mis­lead­ing Viv­it­rol ads — don't for­get vul­ner­a­bil­i­ty to opi­oid over­dose

The ads piqued interest as soon as they started appearing in 2016: at Grand Central Station, on the Red Line in Cambridge, and on a billboard off the New Jersey Turnpike. All showed a young person, generally with his or her arms crossed, and the question, “what is Vivitrol?”

Vivitrol’s maker, Alkermes, was in the midst of a marketing and lobbying campaign to promote the anti-opioid addiction drug — a campaign that would face significant backlash for tarnishing competitors despite little evidence for Vivitrol’s superiority.

FDA in-house re­view spot­lights an is­sue with one of Hori­zon's end­points but notes ef­fi­ca­cy for lead drug

The FDA in-house review highlights a disagreement of investigators’ use of a key endpoint by Horizon Pharma in the late-stage trial for the top drug in its pipeline, but largely agreed that the antibody was effective.

Horizon submitted a BLA for thyroid eye disease (TED) drug teprotumumab in March, less than two years after they bought the drug (and the rest of a division) from Narrow River for $145 million upfront. With breakthrough status, priority review, orphan designation and in-house sales projections of up to $750 million, the one-time Roche reject became the marquee pipeline asset for a company that’s developed some of the world’s most expensive drugs.

Seat­tle Ge­net­ics de­tails pos­i­tive OS and PFS da­ta for tu­ca­tinib in breast can­cer

Seattle Genetics $SGEN is showing off more positive data around tucatinib, its pivotal-stage drug for HER2 positive breast cancer.

A month after hearing about solidly upbeat hazard ratios, we learned today that the estimated progression-free survival rate at one year was 33% in the tucatinib arm compared to 12% for patients taking trastuzumab and capecitabine alone.

Median PFS was 7.8 months (95% CI: 7.5, 9.6) in the tucatinib arm, compared to 5.6 months (95% CI: 4.2, 7.1) in the control arm.

Bat­tered, cash hun­gry In­tec feels the burn of No­var­tis re­jec­tion

It’s a case of some bad timing for Intec.

Just when a key trial testing the company’s Accordion drug delivery tech imploded in Parkinson’s disease, they handed Novartis data from a successful PK study of a custom Accordion pill engineered to deliver a Novartis compound to entice the Swiss drugmaker into signing a licensing agreement.

Novartis said thanks, but no thanks.

For the cash-strapped Israeli drug developer, the failure to clinch the deal marks a big blow. As of the third quarter, the company has $15.7 million in cash and equivalents, which HC Wainwright analysts estimate will keep the lights on into mid-2020.

Bris­tol-My­ers shows off a low-pro­file AML con­tender it gained from Cel­gene buy­out — and they’re tak­ing it straight to the FDA

Bristol-Myers Squibb reaped an enormous pipeline with its much-criticized $64 billion megadeal to buy Celgene. And it got a few hidden gems in the deal.

One of those gems was brought out for display on Tuesday, with a late-breaker at ASH on CC-486, which is now being prepped for regulatory filings at the FDA and elsewhere.

Celgene top-lined the positive results in a maintenance setting for acute myeloid leukemia a few months ago, but at ASH investigators pulled back the curtains on the all-important data they believe will give them an advantage in the commercial wars to come.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.

De­sert­ed by Astel­las and Mer­ck, lit­tle Cor­re­vio still can't win over FDA pan­el con­cerned with its AFib drug's safe­ty

When the FDA spurned Astellas’ pitch for atrial fibrillation drug vernakalant in 2008, regulators made it abundantly clear that it wasn’t the efficacy they had a problem with — two Phase III trials had shown the drug successfully restored 52% of patients’ heartbeat from irregular to normal — but the cardio safety issues for a drug that was to compete with well established, low-risk options. One licensing deal, one clinical hold and several studies later, the chances of approval aren’t looking any better.